

1 Patient Perception of Endoscopic and Medical Therapies for Weight Loss

2  
3 Monica Saumoy MD MS<sup>1</sup>, Yinglin Gao MD<sup>2</sup>, Kelly Allison PhD<sup>3</sup>, Peter F. Cronholm MD MSCE<sup>4</sup>,  
4 Octavia Pickett-Blakely MD MHS<sup>5</sup>, Michael L. Kochman MD<sup>5</sup>, Nikhil R. Thiruvengadam MD<sup>2</sup>

- 5  
6 1. Center for Digestive Health, Penn Medicine Princeton Medical Center, Plainsboro, NJ  
7 2. Division of Gastroenterology and Hepatology, Loma Linda University Health, Loma Linda, CA  
8 3. Department of Psychiatry, Perelman School of Medicine, Philadelphia, PA  
9 4. Department of Family Medicine and Community Health, Center for Public Health, Leonard Davis  
10 Institute for Health Economics, University of Pennsylvania, Philadelphia, PA  
11 5. Division of Gastroenterology and Hepatology and Center for Endoscopic Innovation, Research,  
12 and Training, Perelman School of Medicine, Philadelphia PA

13  
14 Abbreviations used in this paper:

- 15 EBT (endoscopic bariatric therapies)  
16 ESG (endoscopic sleeve gastropasty)  
17 TBWL (total body weight loss)

18  
19 Correspondence to:  
20 Monica Saumoy, MD MS  
21 5 Plainsboro Rd, suite 450  
22 Plainsboro, NJ 08536  
23 Email: [monica.saumoy@pennmedicine.upenn.edu](mailto:monica.saumoy@pennmedicine.upenn.edu)  
24 Fax: 609.853.6390

25  
26 Funding/Grant Support: none

27  
28 Conflicts of interest: The authors have no conflicts to disclose that are relevant to this manuscript

29  
30 Author Contributions:  
31 NT, MS designed the study. LG, MS, collected and distributed the survey. NT and MS performed the  
32 analysis. NT, MS, interpreted the results. NT, MS, wrote the manuscript. NT, MS, LG, MK, KA, PC  
33 revised the manuscript. All authors read and approved the final manuscript.

34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 **Abstract**

45

46 **Background:**

47 For weight management, patient choice has increasingly driven therapeutic options, with less than 1% of eligible  
48 patients choosing bariatric surgery. The aim of this survey was to understand patient perceptions of endoscopic  
49 bariatric therapies (EBTs) and obesity-based pharmacotherapy.

50 **Methods:**

51 An anonymously collected 7-question survey was distributed to gastroenterology patients undergoing screening  
52 colonoscopy.

53 **Results:**

54 A total of 184 patients participated in the survey. Participants demonstrated a greater lack of knowledge of EBTs  
55 (78.2% unaware) compared to pharmacotherapy (35.9% unaware). 40.8% of respondents perceived that EBTs were  
56 not available in the United States. Only 15.8% of respondents recognized that pharmacotherapy requires long-term  
57 treatment to maintain weight loss. Disparities were noted in primarily Spanish-speaking patients demonstrating a  
58 lower awareness of the availability of EBTs in the US (57.6% unaware) and pharmacotherapy (62.1% unaware)  
59 compared to those with English as the primary language.

60 **Conclusions:**

61 Patient knowledge and preference are key to engaging in weight loss therapies. Knowledge gaps regarding weight-  
62 loss options, particularly EBTs, can limit the utilization of all options for the care of patients with obesity.

63

64 **KEYWORDS:** obesity, endoscopic bariatric therapies, survey

65

66

67

68 Rates of obesity have risen exponentially, both in the US and worldwide. In the US, current models predict  
69 that by the year 2030, nearly half of adults will have obesity, and nearly a quarter of adults will have severe obesity.<sup>1</sup>  
70 Current weight loss tools include lifestyle intervention, pharmacotherapy, bariatric surgery, and endoscopic bariatric  
71 therapies (EBTs). Compared to lifestyle intervention, bariatric surgery has been shown to achieve superior weight  
72 loss outcomes, improvement in metabolic comorbidities, and reduced mortality.<sup>2</sup> But, despite the evidence that  
73 bariatric surgery is effective, less than 1% of eligible patients choose to undergo bariatric surgery in the US.<sup>3</sup>

74 Pharmacotherapy provides an alternative weight management strategy, with a variety of medications  
75 demonstrating successful weight loss. Most recently, semaglutide, a glucagon-like peptide-1 agonist, has shown the  
76 most patient-driven interest with an average of 6-17% total body weight loss (TBWL) along with improvement in  
77 markers of cardiovascular health.<sup>4</sup> Another agent, tirzepatide, has demonstrated an average of 15-20.5% TBWL.<sup>5</sup>  
78 Unfortunately, access to pharmacotherapy has been limited due to significant demand, supply chain issues, and lack  
79 of insurance coverage outside of the diagnosis of diabetes.

80 Nationally, there has also been increasing utilization of EBTs, though not as significant as  
81 pharmacotherapy. EBT procedures such as endoscopic sleeve gastroplasty (ESG) and intragastric balloon, have  
82 previously been limited by the lack of insurance coverage. But the recent C code designated by the Centers for  
83 Medicare and Medicaid (CMS) for ESG after the MERIT trial<sup>6</sup> demonstrated clinical success, and has allowed for  
84 increased access. Though there has been a significant body of research demonstrating the effectiveness of EBTs,  
85 there has not been much investigation on improving patient engagement and implementation, as compared with  
86 bariatric surgery.<sup>7, 8</sup>

87 Patients will often turn to their primary care physician (PCP) for advice on how to proceed with weight  
88 management. PCPs are increasingly being asked by patients to prescribe pharmacotherapy for weight loss. And a  
89 recent survey study demonstrated that 76.2% of PCPs discussed bariatric surgery with patients, but 52.3% of PCPs  
90 were not aware of EBTs as weight loss interventions.<sup>9</sup> A critical issue is whether patients' knowledge of EBTs is  
91 similarly restricted, limiting options in shared decision-making discussions with PCPs and engagement with  
92 gastroenterologists. This survey aimed to determine patients' knowledge of EBTs and pharmacotherapy.

93  
94 We performed a questionnaire-based, cross-sectional study of patients at Penn Medicine Princeton Health and at  
95 Loma Linda University system in August 2023. Institution of research ethics board (IRB) approval was obtained.  
96 The questionnaire was developed to determine patient knowledge of endoscopic bariatric therapies and  
97 pharmacotherapy for weight loss. Items were generated following a review of the literature and study team  
98 discussion. Surveys were administered in English and Spanish to patients presenting for outpatient endoscopy – as a  
99 survey of non-targeted patients of the general population. Survey responses were anonymous and managed using  
100 REDCap electronic data capture tools. No identifiable data were collected for the survey respondents and no  
101 incentives were provided for the survey to participants. After completion of data collection, quantitative analysis  
102 was performed using Stata software version (Stata Corp., 2017, Stata statistical software: Release 15. College  
103 Station, Texas).

104

105 184/229 (80.3%) patients completed the survey, which was collected over a one-month period. Spanish was the  
106 primary language for **36%** of respondents. (Table 1) Most of the respondents (**78.3%**) were unaware of endoscopic  
107 procedures to help patients lose weight. A fraction of respondents had heard of the ESG (26.1%) or intragastric  
108 balloon (29.9%). A total of 40.7% of respondents believed that EBT was not available in the US. In contrast, 64.1%  
109 of respondents had previously heard of medications for weight loss. Though only 15.8% recognized that medications  
110 for weight loss needed to be continued long-term for maintenance. And only 34.2% of respondents stated that  
111 pharmacotherapy could successfully improve obesity-related medical comorbidities. Spanish-speaking individuals  
112 had lower rates of awareness of ESG (89% unaware), intragastric balloon (84.8% unaware), or knowledge of  
113 effective pharmacotherapy (62.1% unaware) compared to English-Speaking individuals. (Figure 1)

114  
115 This survey investigated patient knowledge regarding endoscopic therapies for weight management. The  
116 survey demonstrated that a majority of patients (78.2%) were unaware of EBTs for weight management and had not  
117 heard of either ESG or intragastric balloon. Though a significantly higher proportion of patients (64.1%) were aware  
118 of medication therapy for weight loss, most respondents were not aware that weight-loss medications require long-  
119 term use for weight-loss maintenance.

120 Management of obesity and related complications has been an increasingly common indication for medical  
121 visits due to the obesity epidemic. Providers recognize that obesity is a complex disease that requires multimodal  
122 therapy, including clinicians specializing in medical, surgical, and endoscopic therapies, as well as dieticians,  
123 exercise therapists, and behavioral psychologists. However, access to such comprehensive centers is limited due to  
124 provider availability. If multidisciplinary centers are unavailable, referral patterns are driven by providers to singular  
125 centers, such as a bariatric surgery group or a gastroenterologist for endoscopic bariatric therapy. Despite the  
126 reported efficacy of EBTs, there is still a limited number of patients being referred for gastroenterologist evaluation.  
127 Knowledge gaps and consumer demand driving PCP referral patterns are likely responsible, as a recent survey study  
128 demonstrated that while 72.6% of PCPs discussed bariatric surgery as an option for weight loss, 52.3% of PCPs  
129 were not aware of EBTs, and only 24.6% of PCPs were familiar with the indications for EBTs.<sup>9</sup> PCPs are typically  
130 the first medical providers to initiate patient discussions about obesity and the indications for weight loss. Therefore,  
131 provider education on EBTs will be key for improving patient uptake in weight loss therapies.

132 Patient preference is a significant factor to drive patient engagement and treatment decision-making.  
133 Patient preference is typically a combination of what therapies patients have been exposed to, either from their  
134 providers, friends/family, social media, or the lay press. Shared decision-making with patients and their providers is  
135 a key component of patient engagement. Patients who are engaged in chronic illness management, have  
136 demonstrated improvement in mortality.<sup>10</sup> If patients are unaware of potential weight loss therapies, this can limit  
137 optimal care of this patient population. In our survey, only 21.7% of respondents recognized that EBT is an option  
138 for weight loss, demonstrating a significant knowledge gap. The knowledge gap widens for patients for whom  
139 English is not their primary language. This survey adds to the current body of literature that there are significant  
140 disparities related to language barriers in healthcare, which limits compliance and successful clinical outcomes.<sup>11, 12</sup>  
141 Patient engagement tools and decision aids have been utilized in other clinical scenarios to support and help patients

142 make medical decisions and include key clinical content for patient understanding.<sup>13</sup> This suggests that targeted  
143 educational programs, in their primary language, to educate patients on comprehensive treatment options for weight  
144 loss (surgery, pharmacotherapy, and EBTs) may improve patient access and engagement.

145         Pharmacotherapy provides an adjunctive weight management strategy, with a variety of medications  
146 demonstrating successful weight loss. In addition to success in clinical trials, there have been numerous reports in  
147 the media about celebrity use of pharmacotherapy, which has driven overall public interest. However, it is unclear  
148 what the public understands regarding pharmacologic weight management. Specifically, medication therapy needs  
149 to be continued indefinitely as demonstrated in the STEP4 trial which showed rapid weight regain when semaglutide  
150 was discontinued.<sup>14</sup> In our study, only 15.8% of respondents recognized that pharmacotherapy requires long-term  
151 use to maintain weight loss. However, there are serious cost concerns with the use of these medications, resulting in  
152 limited insurance coverage in the US. A recent cost-effectiveness study demonstrated that long-term therapy with  
153 semaglutide is currently not cost-effective at a willingness-to-pay threshold of \$100,000/QALY due to its high  
154 annual cost.<sup>15</sup> Indeed, the National Institute for Health Care Excellence in the UK approved only a limited 2-year  
155 course of semaglutide based on an industry-sponsored analysis demonstrating that a 2-year course of semaglutide  
156 was cost-effective compared to lifestyle intervention in patients with obesity and at least one comorbidity.<sup>16</sup> But as  
157 suggested by the STEP4 trial, planned discontinuation has the risk of rapid weight regain. The risk of rapid weight  
158 cycling is likely increased by multiple factors: poor insurance coverage, high out-of-pocket costs, limited access to  
159 long-term use of the medication, and lack of patient knowledge of the need to continue pharmacotherapy to maintain  
160 long-term weight loss. In turn, rapid weight cycling may increase depressive symptoms,<sup>17</sup> risk of cardiovascular  
161 disease, and all-cause mortality.<sup>18</sup>

162         Due to the rise in obesity and the simultaneous need for weight loss therapies, engagement by all key  
163 stakeholders is necessary for the management of patients with obesity and obesity-related complications. However,  
164 knowledge gaps regarding EBTs, incorrect and inadequate perceptions of pharmacologic weight therapies, limited  
165 access to dedicated bariatric centers, and lack of financial coverage, can limit the optimal care of this patient  
166 population. Targeted educational programs to educate patients and providers on the most current guidelines and  
167 weight loss interventions may improve patient access and engagement. While knowledge and awareness are critical  
168 aspects of behaviors, much more is required to support adaptive changes in behaviors that can result in meaningful  
169 and sustained weight loss.

170

171

172

173

174 **Captions:**

175  
176 Table 1. Survey administered to patients with collected responses. Survey responses tabulated as all  
177 responses and responses of patients with Spanish as their primary language.

178  
179 Figure 1. Bar graph demonstrating patient responses to survey questions separated between English and  
180 Spanish-speaking patients.

181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201

202 **References**

- 203 1. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult  
204 Obesity and Severe Obesity. *N Engl J Med* 2019;381:2440-2450.
- 205 2. Chang D-M, Lee W-J, Chen J-C, et al. Thirteen-year experience of laparoscopic sleeve  
206 gastrectomy: surgical risk, weight loss, and revision procedures. *Obesity surgery*  
207 2018;28:2991-2997.
- 208 3. Martin M, Beekley A, Kjorstad R, et al. Socioeconomic disparities in eligibility and  
209 access to bariatric surgery: a national population-based analysis. *Surg Obes Relat Dis*  
210 2010;6:8-15.
- 211 4. Gao X, Hua X, Wang X, et al. Efficacy and safety of semaglutide on weight loss in obese  
212 or overweight patients without diabetes: A systematic review and meta-analysis of  
213 randomized controlled trials. *Front Pharmacol* 2022;13:935823.
- 214 5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment  
215 of Obesity. *N Engl J Med* 2022;387:205-216.
- 216 6. Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Endoscopic sleeve gastroplasty for  
217 treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.  
218 *Lancet* 2022;400:441-451.
- 219 7. Chee A, Abdel-Rasoul M, Zoretich K, et al. Bariatric Patient Engagement in a Pre-  
220 surgery Virtual Patient Navigation Platform (VPNP). *Obes Surg* 2023.

- 221 8. Musbahi A, Clyde D, Small P, et al. A Systematic Review of Patient and Public  
222 Involvement (PPI) in Bariatric Research Trials: The Need for More Work. *Obes Surg*  
223 2022;32:3740-3751.
- 224 9. Ouni A, Khosla AA, Gomez V. Perception of Bariatric Surgery and Endoscopic Bariatric  
225 Therapies Among Primary Care Physicians. *Obes Surg* 2022;32:3384-3389.
- 226 10. Krist AH, Tong ST, Aycock RA, et al. Engaging Patients in Decision-Making and  
227 Behavior Change to Promote Prevention. *Stud Health Technol Inform* 2017;240:284-302.
- 228 11. Rosen CB, Roberts SE, Sharpe J, et al. A study analyzing outcomes after bariatric surgery  
229 by primary language. *Surg Endosc* 2023;37:6504-6512.
- 230 12. Kroner Florit PT, Corral Hurtado JE, Wijarnpreecha K, et al. Bariatric Surgery, Clinical  
231 Outcomes, and Healthcare Burden in Hispanics in the USA. *Obes Surg* 2019;29:3646-  
232 3652.
- 233 13. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or  
234 screening decisions. *Cochrane Database Syst Rev* 2017;4:CD001431.
- 235 14. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous  
236 semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity:  
237 the STEP 4 randomized clinical trial. *Jama* 2021;325:1414-1425.
- 238 15. Saumoy M, Gandhi D, Buller S, et al. Cost-effectiveness of endoscopic, surgical and  
239 pharmacological obesity therapies: a microsimulation and threshold analyses. *Gut* 2023.
- 240 16. National Institute for Health and Care Excellence . (2022). Semaglutide for managing  
241 overweight and obesity [https://www.nice.org.uk/guidance/gid-ta10765/documents/final-](https://www.nice.org.uk/guidance/gid-ta10765/documents/final-appraisal-determination-document)  
242 [appraisal-determination-document](https://www.nice.org.uk/guidance/gid-ta10765/documents/final-appraisal-determination-document).
- 243 17. Quinn DM, Puhl RM, Reinka MA. Trying again (and again): Weight cycling and  
244 depressive symptoms in U.S. adults. *PLoS One* 2020;15:e0239004.
- 245 18. Oh TJ, Moon JH, Choi SH, et al. Body-weight fluctuation and incident diabetes mellitus,  
246 cardiovascular disease, and mortality: a 16-year prospective cohort study. *The Journal of*  
247 *Clinical Endocrinology & Metabolism* 2019;104:639-646.
- 248

# Comparison of Survey Responses Between Spanish-Speaking and English-Speaking Patients

